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1. Introduction  
Following transmission, the human immunodeficiency virus (HIV) initiates persistent 
infection by integrating into the genome of host cells. To date it has not been possible to 
clear these cells by anti-viral or immune therapy, during either active or latent infection. 
This makes design of an efficacious HIV vaccine exceedingly difficult, since complete 
prevention of infection, or “sterilizing immunity”, is required. As cellular immunity targets 
already infected cells, humoral immune responses which can prevent initial infection by 
means of anti-envelope neutralizing antibodies have been a prime focus of vaccine 
development. In proof of concept studies, passive administration of potent neutralizing 
antibodies has prevented infection of non-human primates by intravenous and mucosal 
routes (Mascola et al., 1999; Baba et al., 2000; Mascola et al., 2000; Parren et al., 2001), 
validating the research focus on neutralizing antibody induction. However, the task of 
designing an envelope vaccine is complicated by the extreme variability among HIV 
isolates, the propensity for neutralization escape resulting from immune pressure exerted by 
induced antibodies, conformational features of the HIV envelope which make immunogen 
design difficult, and additional envelope characteristics which effectively hide areas of 
vulnerability which might ordinarily be antibody targets.  There are several excellent recent 
reviews covering the issue of broadly neutralizing antibodies (Mascola & Montefiori, 2010; 
Walker & Burton, 2010; Zolla-Pazner & Cardozo, 2010; McElrath & Haynes, 2010) and it is 
not the intent of this review to reproduce that information. Rather, we will briefly 
summarize some of the salient issues and approaches, and then discuss more extensively 
non-neutralizing anti-envelope antibodies. 
Broadly neutralizing antibodies are difficult to elicit by vaccination. But the HIV envelope 
protein is quite immunogenic, and an array of non-neutralizing antibodies is induced by 
both natural infection and vaccination. Through use of sensitive new methods, these 
antibodies have exhibited several functional activities associated with protection. In serum 
these include antibody-dependent cellular cytotoxicity (ADCC) (Weinhold, 1990) and 
antibody-dependent cell mediated viral inhibition (ADCVI) (Forthal et al., 2006). Secretory 
antibodies have also been associated with protection via mechanisms such as transcytosis 
inhibition (Bomsel et al., 1998). Augmented by high avidity and recall memory responses 
which improve their efficacy, these antibody activities can contribute in varying degrees to 
vaccine-induced protective efficacy. The main thrust of this review will be to examine these 
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non-neutralizing antibody responses in HIV and SIV infection and following vaccination, to 
describe how they may contribute to protection, and to summarize their potential utility 
amidst the array of additional immune protective mechanisms available to the host, 
including innate, cellular, and mucosal immunity.  
2. Neutralizing antibodies 
The variability of the HIV envelope is notorious. The envelope exhibits a 30% difference 
in amino acid sequence between the 9 clades designated A – K, omitting E and I (Korber 
et al., 2001). Envelope diversity within clades can be as high as 20% (Mascola & 
Montefiori, 2010). Therefore the goal of eliciting anti-envelope antibodies able to broadly 
recognize and protect against this spectrum of isolates is daunting. In fact it is difficult to 
induce broadly neutralizing antibodies by vaccination. Most that arise are relatively 
weak and only able to neutralize the most sensitive or easy to neutralize “Tier I” isolates 
(Mascola et al., 2005; Seaman et al., 2010). Yet recent publications document development 
of cross-reactive neutralizing antibodies during HIV infection (Sather et al., 2009) with 20 
to 34% of HIV-infected individuals possessing significant breadth (Simek et al., 2009; 
Doria-Rose et al., 2010).  That vaccine induction of broadly neutralizing antibodies is a 
realistic goal is also illustrated by the isolation of a handful of naturally elicited 
antibodies that recognize a wide spectrum of HIV isolates.  These include b12, an 
monoclonal antibody selected by random reassortment of a phage library which 
recognizes the CD4 binding site of the HIV envelope (Burton et al.,  1994); 2G12, a 
monoclonal antibody that recognizes carbohydrate moieties (Trkola et al., 1996) on the 
silent face of the envelope; and monoclonal antibodies 2F5 and 4E10 that target the 
membrane-proximal external region (MPER) of the viral envelope transmembrane 
protein (Muster et al., 1993; Zwick et al., 2001). Additionally, the V3 region of the 
external envelope protein gp120, originally believed to elicit only type-specific 
neutralizing antibodies, has been shown to elicit broader responses. A panel of V3 
monoclonal antibodies including 447-52D was recently reported to exhibit significant 
cross-clade neutralizing activity (Hioe et al., 2010). The basis for this breadth may be the 
conserved structural elements in the V3 loop which provide for its essential function as 
part of the binding region to chemokine co-receptors and which outweigh the inherent 
variability of the amino acid sequence in importance (Almond et al., 2010; Jiang et al., 
2010). Portions of the V3 and V2 loops comprise a novel quaternary epitope, recognized 
only as part of the native trimer.  Monoclonal antibody 2909, the first such described 
human antibody, is potent but relatively strain specific (Gorny et al., 2005). In contrast, 
the recently identified monoclonals PG9 and PG16 (Walker et al., 2009) also recognize 
quarternary epitopes, but differ by exhibiting great neutralization breadth, attributed to 
dependence on an asparagine-linked carbohydrate moiety at residue 160 in the V2 loop. 
The 2909 antibody recognizes a lysine at this position (Zolla-Pazner & Cardozo, 2010). 
New methods of high-throughput monoclonal antibody cloning and screening have 
facilitated isolation of several additional broadly neutralizing antibodies (Scheid et al., 2009; 
Corti et al., 2010). To date VRC01, a CD4 binding site antibody, has shown the greatest 
breadth, neutralizing 91% of tested HIV isolates, representative of all major HIV clades (Wu 
et al., 2010). Structural knowledge of the HIV envelope, computer-assisted protein design, 
and state-of-the-art methods for memory B cell sorting and single cell PCR facilitated its 
isolation.  It is hoped that similar new methodologies can lead to design of an appropriate 
vaccine component able to elicit neutralizing antibody breadth. 
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2.1 Development of neutralizing antibodies in natural infection  
While a significant percentage of HIV-infected individuals with chronic disease have a 
degree of neutralizing antibody breadth, a much smaller percentage are able to neutralize 
across all HIV clades (Simek et al., 2009). Long-term non-progressors have rather poor 
neutralizing antibody responses. Rather potent neutralizing activity seems to require a 
lengthy time period of sustained viremia and development of strong binding avidity, 
suggesting that antigen persistence and antibody maturation are needed for development of 
a broad response (Sather et al., 2009). Neutralizing antibodies develop very slowly in HIV-
infected individuals. Antibodies with specificity for gp41 appear first at around 13 days 
post-infection and anti-gp120 antibodies at around day 28 (Tomaras et al., 2008). However, 
neutralizing antibodies appear later, usually months after infection, and thus do not appear 
to control viremia (Aasa-Chapman et al., 2004; Gray et al., 2007). This slow development 
reflects, at least in part, the same obstacles facing vaccine-induction of a neutralizing 
antibody response: conformational and carbohydrate masking of critical epitopes; homology 
of some epitopes with self proteins, leading to polyreactive antibodies that are subject to 
immune tolerance; and envelope variability leading to immune selective pressure and viral 
escape (McElrath and Haynes, 2010). Later in the course of disease, loss of CD4 help and B 
cell dysfunction exacerbates the poor neutralizing antibody development (Alter and Moody, 
2010).  
2.2 Improved envelope immunogen design  
In addition to improved envelope design based on increasing knowledge of the structure of 
the HIV envelope, other approaches have attempted to better expose critical conserved 
epitopes on envelope immunogens. These have included deletion of variable loops to 
expose otherwise hidden regions of the envelope; alteration of glycosylation patterns to 
prevent masking; preparation of trimeric forms of the envelope to mimic the natural 
structure on the surface of the virion, and introduction of critical epitopes on other scaffolds 
for better presentation to the immune system (Hu and Stamatatos, 2007). These alterations 
have had varying degrees of success, although none has induced the breadth and potency of 
neutralizing antibody response needed for a highly effective vaccine. It is hoped that 
continued improvements in envelope immunogens fostered by greater knowledge of 
envelope structure and understanding of the natural process of broadly neutralizing 
antibody induction will achieve the desired goal.  
3. Non-neutralizing antibodies 
The RV144 phase III trial in Thailand which assessed an ALVAC–recombinant prime/Env 
protein boost regimen, showed only modest efficacy, protecting 31% of vaccinated 
individuals in the intent-to-treat group (Rerks-Ngarm et al., 2009). Nevertheless, this 
outcome provided the first evidence that development of a safe and effective preventive 
HIV vaccine is possible. This study also highlighted the need to better understand immune 
correlates of protection associated with decreased HIV acquisition. The RV144 vaccine 
components have induced a broad constellation of immune responses, including T-cell–line 
adapted neutralizing antibody (Nitayaphan et al., 2004), antibody-dependent cell-mediated 
cytotoxicity (Karnasuta et al., 2005), and CD4+ and CD8+ T cell responses, but clear immune 
correlates have not been defined. Currently in order to combat the extensive genomic 
diversity of HIV both strong cellular and humoral immune responses are believed necessary 
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for a successful vaccine (Amanna & Slifka, 2010; Benmira et al., 2010). However, as strong 
cellular immunity was not elicited in the majority of RV144 vaccinees, humoral immunity is 
believed to have contributed to the protection against HIV acquisition. As the vaccine 
regimen did not elicit antibodies able to neutralize primary HIV isolates, the focus of 
research has shifted to the potential for non-neutralizing antibodies to mediate protection. 
Neutralizing antibodies are able to prevent infection of susceptible cells; however, once a 
cell is infected it is difficult to imagine a role for neutralizing antibodies (Battle-Miller et al., 
2002). Other antibody functions such as ADCC and ADCVI working together with innate 
effector cells provide a means to target and kill virus infected cells (Fig. 1A). Such 
mechanisms could control or possibly eradicate the small foci of infected cells that form in 
the lamina propria after viral transmission and prior to systemic spread of the virus (Fig. 1B; 
Haase, 2005). 
3.1 ADCC 
ADCC bridges innate and adaptive immunity. It involves effector cells able to mediate cell 
lysis, target cells expressing cell surface antigen, and specific antibody that recognizes the 
cell surface antigen and activates effector cells via interaction with Fc receptors. The 
interaction between the Fc domain of the antibody and the corresponding receptor on 
effector cells triggers a series of events that lead to the destruction of the infected cell via 
cytotoxic granules (perforin, granzyme) or a death-receptor-dependent pathway (Fas/Fas 
ligand; TNF/TNFR) (de Saint Basile et al., 2010; Chavez-Galan et al., 2009).  
Most ADCC responses described in the literature are directed against the envelope protein 
(Env) (Ahmad & Menezes, 1996; Baum et al., 1996; Alsmadi & Tilley, 1998), although Nef 
(Yamada et al., 2004) and Tat (Florese et al., 2009) have also been shown to be ADCC targets. 
Additionally, a recent study in chronically infected subjects reported that Pol is an ADCC 
target, but this Pol-specific ADCC activity did not correlate with delayed HIV progression 
(Isitman et al., 2010). Moreover, the pol gene encodes internal proteins, so it is possible that 
the Pol-specific ADCC activity observed was targeting by-stander cells that had scavenged 
dead-cell debris. Despite the potential efficacy of ADCC, little is known about specific 
epitopes recognized by antibodies able to mediate ADCC. Epitopes recognized by both anti-
Env and anti-Nef antibodies that mediate ADCC have been described (Alsmadi et al., 1997; 
Yamada et al., 2004; Los Alamos National Laboratory Molecular Immunology Database). As 
discussed below, anti-Env antibodies that mediate ADCC have been associated with 
protection, however, whether anti-Nef or anti-Tat antibodies have an impact on natural 
infection is not known.  
Effector cells that mediate ADCC are not major histocompatibility complex restricted, and 
multiple subpopulations of peripheral blood mononuclear cells (PBMCs) are involved in 
mediating ADCC function. NK cells, ┛├ T cells, neutrophils, monocytes, and macrophages 
all express the Fc receptor that can engage antibodies (Forthal & Moog, 2009). A large 
number of these cells are always present in peripheral tissues, in contrast to memory B and 
T cells in lymphoid tissue which require activation for neutralizing antibody or T cell 
functions. Since HIV infection rapidly spreads during the first 2 weeks after transmission, 
the significant time advantage provided, for example, by pre-existing vaccine-elicited 
antibody and Fc receptor-bearing cells, may facilitate better control of viremia. IgG1 and 
IgG3 are the most common IgG isotypes to mediate ADCC via strong interaction with the 
Fc-binding receptor CD16/Fc┛RIII expressed mainly on NK cells (Niwa et al., 2005).  
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Traditionally, ADCC killing was assessed using assays in which target cells were labeled 
with radioactive isotopes such as 51Chromium. Disadvantages of this method include 
difficulty labeling certain cell types, low assay sensitivity and high spontaneous chromium 
release resulting in high background values (Volgmann et al., 1989). Several flow cytometry-
based alternatives have recently circumvented the problems associated with radioactive 
labeling of target cells in cytotoxicity assays (Wilkinson et al., 2001; Gomez-Roman et al., 
2006a; Stratov et al., 2008; Chung et al., 2009). These assays have provided greater ease of 
use and importantly greater sensitivity, facilitating investigation of the role of ADCC 
activity in natural infection and vaccine-induced protection. 
3.1.1 HIV-specific ADCC responses in natural infection  
Over the past 20 years, the dogma that T cells and neutralizing antibodies are protective 
immune correlates for many vaccines led to lack of interest in the ADCC mechanism. 
However the gradual accumulation of evidence from natural infection and vaccine studies 
supporting a protective role for ADCC has stimulated studies of this immune response. A 
number of early studies documented the induction of ADCC antibodies during HIV 
infection (Lyerly et al., 1987; Rook et al., 1987; Ojo-amaize et al., 1987). A potential role for 
ADCC in modulating the course of HIV infection was eventually suggested based on studies 
showing an inverse association between ADCC antibody levels and clinical stage of the 
disease. Baum et al, (1996) presented strong evidence that higher titers of antibodies 
mediating ADCC correlated with a successful host defense against HIV-1, and Forthal et al., 
(2001a) reported an inverse association between ADCC activity and plasma viremia. Higher 
ADCC activity has also been correlated with slower disease progression in children 
(Ljunggren et al., 1990; Broliden et al., 1993). More recently, ADCC activity has been 
demonstrated in cervical lavage fluids of HIV-infected women (Battle-Miller et al., 2002), 
and associated with lower genital HIV RNA loads (Nag et al., 2004). Elite controllers also 
have higher ADCC antibody titers than viremic individuals, whereas neutralizing antibody 
activity tends to be higher in viremic individuals (Lambotte et al., 2009). Nevertheless, not 
all studies have concluded that ADCC plays a role in protective efficacy (Dalgleish et al., 
1990; Lifson et al., 1991; Chuenchitra et al., 2003). The conflicting results reflect the 
complexity of the virus-host interaction and elements that contribute to the ADCC response, 
including the integrity of the host immune system, extent of viremia, level and affinity of 
antibodies induced, and functionality of effector cells.  
3.1.2 ADCC responses in non-human primate models 
Non-human primate studies have stimulated interest in the ADCC mechanism and its role 
in protective efficacy. ADCC activity has been correlated with delayed disease progression 
in SIV infected macaques (Banks et al., 2002). Additional convincing evidence has come 
from pre-clinical vaccine studies. A replicating adenovirus type 5 host range mutant 
(Ad5hr)-SIV recombinant prime/SIV gp120 protein boost regimen was shown to elicit 
potent protection against an intrarectal SIVmac251 challenge (Patterson et al., 2004). The 
vaccine did not induce antibodies able to neutralize primary SIVmac251, however, the reduced 
acute viremia was significantly correlated with anti-envelope binding antibodies that 
mediated ADCC against SIVmac251-infected cells (Gomez-Roman et al., 2005). Subsequent 
studies, one involving a comparison of Ad5hr-SIV recombinant priming via the upper 
respiratory tract versus the oral route followed by SIV gp120 boosting and SIVmac251 
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challenge, and another involving a comparison of Ad5hr-recombinant priming with and 
without subsequent envelope protein boosting followed by challenge with the chimeric 
virus SHIV89.6P, again showed significant correlations of ADCC activity with reduced acute 
viremia (Hidajat et al., 2009; Xiao et al., 2010). The latter study also revealed a correlation of 
ADCC activity with reduced chronic viremia. The importance of antibody maturation in 
induction of the functional antibody responses was indicated by the significant correlation 
of ADCC-mediating antibodies with binding antibody avidity.   
The non-human primate model provides a good mimic for exploration of vaccine strategies 
and immune mechanisms. For example, passive antibody transfer studies can directly 
explore the ability of antibodies to mediate protection. Binley et al. (2000) observed that 
passive infusion of IgG to rapid and normal progressor SIVmac251 infected animals caused 
small and transient reductions in plasma viremia by a mechanism that was inconsistent with 
virus neutralization but which could have been effector cell mediated, implicating ADCC. In 
contrast, infusion of IgG possessing high titers of anti-Env antibodies able to mediate ADCC 
had no effect on viral loads following two sequential oral challenges of neonatel macaques 
with SIVmac251 (Florese et al., 2006). In both these studies, high viral loads may have 
contributed to negligible protective effects. Further, the neonatal macaque study may have 
been compromised by low levels and poorly functioning effector cells in the baby animals. 
An improved experimental design using repetitive low dose challenge might yield more 
significant results.  
Passive transfer of monoclonal antibodies has proven more informative in elucidating 
mechanisms of antibody-mediated protection. An elegant study by Hessell et al. (2007) 
using the neutralizing b12 monoclonal antibody and a mutant unable to bind the Fc receptor 
and complement, showed that protection from a SHIVSF162P3 challenge mediated by the b12 
antibody was in part due to Fc-mediated effects. A follow-on study using low-titered b12, 
mutant antibody, and low-dose repeated SHIVSF162P3 challenge, supported a contribution of 
effector function to the delayed acquisition observed (Hessell et al., 2009).  
As illustrated by the b12 monoclonal, neutralizing antibodies may also mediate ADCC 
activity via their Fc domain. However, all ADCC mediating antibodies do not necessarily 
possess neutralizing activity. A neutralizing antibody must target a specific region of the 
viral envelope, whereas antibodies that mediate ADCC are required only to recognize an 
exposed target epitope on the surface of the infected cell. Antibodies elicited in chimpanzees 
to an HIV clade B immunization regimen were able to mediate ADCC killing of clade A, B, 
C, and AE env-expressing target cells (Gomez-Roman et al., 2006). Therefore, in addition to 
the ability to rapidly respond, the ADCC effector mechanism can provide the breadth of 
antibody recognition believed necessary for protective efficacy. 
The extent to which the ADCC mechanism contributes to vaccine-induced protection is not 
yet clarified. A definitive conclusion will perhaps come from immune correlates identified 
in human clinical vaccine trials. To date only a few such trials have evaluated ADCC 
activity. Goepfert et al. (2007) reported that Env-specific ADCC activity, correlated with 
binding antibodies, was detected in most individuals that received a candidate AIDS 
vaccine containing gp120. Further, as mentioned above, a phase II human trial in Thailand 
has shown induction of ADCC mediating antibodies (Karnasuta et al., 2005). The role of 
these antibodies in the protection against HIV acquisition seen in the RV144 trial which used 
similar immunogens is currently being actively explored. 
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Fig. 1. Control of viral infection by non-neutralizing antibodies. A. ADCC and ADCVI. 
(1)Fc receptors on effector cells recognize the Fc domain of antibody bound to antigen on 
infected cells, inducing release of cytotoxic granules and cell lysis via ADCC. (2) Activation 
of effector cells may lead to production of chemokines and cytokines and viral inhibition by 
ADCVI. B. A mucosal surface with a single layer of columnar epithelium. Viral 
transmission may occur by  transcytosis of cell-free (1) or cell-associated virus (2). T cells, 
effector cells (macrophages, monocytes, NK cells, ┛├ T-cells, neutrophils) and plasma cells 
are present in the lamina propria. Mucosal antibodies, secreted by plasma cells (3), may 
block infection by neutralizing virus (4), or by blocking transcytosis of cell-associated (5) or 
cell-free virus (6). Antibodies can mediate ADCC and ADCVI to eradicate or control infected 
cell foci, blocking dissemination of virus to lymph nodes (7).  
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3.2 ADCVI 
Like ADCC, ADCVI requires antibody that forms a bridge between an infected target cell 
and an Fc┛R-bearing effector cell (Forthal et al., 2001). However, ADCVI is a broader activity 
not restricted to target cell lysis, as with ADCC. Rather it encompasses several mechanisms 
by which viral replication following target cell infection is inhibited. These may include 
ADCC activity, but also noncytolytic mechanisms of virus control, such as secretion of 
inhibitory chemokines (Fig. 1A), or Fc┛R-mediated phagocytosis of immune complexes. The 
readout in ADCVI assays is the percentage of virus inhibition due to effector cells together 
with a test antibody relative to a negative control antibody. This biological endpoint allows 
assessment of ADCVI against any lentiviral strain able to infect cells. As the ADCVI assay 
uses heat-inactivated serum, complement activities do not play a role (Forthal & Landucci, 
1998). Overall, ADCVI is a measure of the combined ability of antibody and effector cells to 
inhibit the spread of virus infection (Forthal et al., 2001; Forthal & Moog, 2009). Both 
polyclonal and monoclonal antibodies can mediate ADCVI. Intact IgG, not just the F(ab’)2 
portion is required (Forthal et al., 2006), emphasizing the importance of Fc-Fc receptor 
interactions in mediating the functional activity.  
3.2.1 ADCVI during HIV infection 
ADCVI has been associated with reduction in viremia during HIV infection. In HIV-infected 
individuals, systemic non-neutralizing antibodies appear early during acute infection, 
generally before a neutralizing antibody response (Sawyer et al., 1990). Not surprisingly, in 
individuals with acute HIV infection, non-neutralizing ADCVI antibodies appeared as early 
as the first week after onset of symptoms or the first month after HIV exposure (Forthal et 
al., 2001). ADCVI activity became more potent as the viral load fell (in the absence of 
antiretroviral therapy), resulting in an inverse relationship between ADCVI activity and 
acute plasma viremia, suggesting a protective effect. Importantly, ADCVI antibodies 
appeared to be broadly reactive with different HIV strains. The demonstration of an 
association between non-neutralizing but functional antibodies able to mediate ADCVI 
activities and protection is noteworthy and timely, in view of the recent outcome of the 
RV144 phase IIb vaccine trial in Thailand as discussed above.  A previous study of serum 
samples from the Vax004 trial which evaluated gp120 vaccines similar to those used for 
boosting in RV144 revealed an inverse correlation between the HIV infection rate of 
vaccinated individuals and vaccine-elicited ADCVI antibody activity (Forthal et al., 2007). 
Although this trial did not result in protection, the results support the hypothesis that 
similar functional antibody activities may have contributed to protection in the RV144 trial. 
Taken together, these observations have renewed interest in defining the mechanisms of 
Fc┛R-mediated protection by ADCC and ADCVI. 
3.2.2 ADCVI in rhesus macaque models 
In support of a protective role for ADCVI, significant correlations between ADCVI activity 
mediated by vaccine-induced antibodies and decreased acute viremia have been reported in 
both SIV and SHIV rhesus macaque models (Florese et al., 2009; Hidajat et al., 2009; Xiao et 
al., 2010). Further, passive infusion of anti-SIV immune serum with strong ADCVI activity 
to newborn rhesus macaques prevented infection from an oral SIVmac251 challenge (Forthal et 
al., 2006). A recent study showed that vaccine-elicited antibody mediated ADCVI activity 
that was recalled 4 weeks post-challenge. This post-challenge activity was correlated with 
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reduced chronic phase viremia (Xiao et al., 2010) suggesting a broader role for ADCVI in 
controlling viral replication over the course of disease rather than impacting only early post-
transmission viral spread. In this same study, a negative correlation between ADCVI 
activity 4 weeks post-challenge and neutralizing antibody titer 8 weeks post challenge was 
observed which became progressively weaker over time, and disappeared by 24 weeks post-
challenge. The ADCVI assay evaluates viral inhibition in the presence of serum plus effector 
cells, and subtracts inhibition observed with serum in the absence of effector cells. This latter 
inhibition is attributed to neutralizing antibody. Therefore, the inverse correlation between 
the two activities might indicate that both neutralizing and non-neutralizing antibodies 
were mediating ADCVI. Neutralizing monoclonal antibodies are known to mediate ADCVI 
activity (Hessell et al., 2007). Development of de novo neutralizing antibody depends on the 
presence of sufficient viral antigen to drive the antibody response. The inverse relationship 
between ADCVI and the more slowly developing neutralizing antibody may reflect control 
of viremia by ADCVI and/or other immune mechanisms at the expense of strong 
neutralizing antibody induction due to a reduced viral burden. The complexity of the in vivo 
situation makes the relationships between functional antibody activities and viral burden 
difficult to resolve. 
4. Secretory antibody 
Mucosal surfaces are the major site for HIV entry. Therefore, an effective HIV vaccine may 
require the presence of antibodies able to prevent infection at mucosal sites. IgA antibodies 
are the most prevalent at mucosal surfaces, and might contribute to protection by one or 
more mechanisms including classical neutralization, but also non-neutralizing activities 
such as immune exclusion involving mucus entrapment and clearance, ADCC discussed 
above, and inhibition of HIV transcytosis across the epithelial cell barrier (Fig. 1B; 
Kozlowski and Neutra, 2003). Study of HIV-exposed but uninfected individuals (so called 
highly-exposed, seronegative; or HEPS), has shown the presence of functional HIV-specific 
IgA at mucosal surfaces of these individuals (Miyazawa et al., 2009; Lopalco, 2004), 
implicating the antibody in resistance to HIV infection.  
Several vaccine approaches have been evaluated in non-human primates for the ability to 
elicit viral-specific IgA antibodies at genital/rectal sites. These have included tonsillar 
immunizations with replication-defective SIV (Vagenas et al., 2009), administration of DNA 
vaccines intranasally or rectally, followed by boosting with MVA recombinants (Bertley et 
al., 2004; Wang et al., 2004), intradermal or intramuscular administrations of DNA vaccines 
together with GM-CSF DNA or CCL27 DNA as adjuvants (Lai et al., 2007; Kraynyak et al., 
2010) vaginal delivery of trimeric HIV envelope together with Carbopol gel (Cranage et al., 
2011), upper respiratory track immunization with replication-competent Ad-recombinants 
followed by intramuscular boosting with envelope protein (Florese et al., 2009; Hidajat et al., 
2009; Xiao et al., 2010), and intramuscular plus intranasal immunization with a gp41 subunit 
vaccine delivered on virosomes (Bomsel et al., 2011). These have had varying degrees of 
success in consistently eliciting mucosal IgA antibodies. Only a few studies, however, have 
investigated functionality of vaccine-elicited IgA as discussed below. Immune exclusion is 
difficult to assess in vitro due to the necessity for a mucus barrier, but neutralizing, ADCC, 
and ADCVI activities can be evaluated. Transcytosis inhibition seems especially relevant for 
mucosal protection.  
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4.1 Transcytosis inhibition 
HIV-1 transmission mainly occurs through exposure of mucosal surfaces to HIV-infected 
fluids, such as semen, cervicovaginal fluid, saliva, colostrum, and breast milk (Pope and 
Haase, 2003). A key entry event is translocation of virus across the epithelium. In rectal, 
intestinal, colonic, and endocervical mucosa, the epithelium is made up of a single layer of 
polarized, columnar epithelial cells with tight junctions separating the cells into the apical 
domain, which faces the lumen, and the basolateral domain, which faces the serosal side 
and the internal milieu (Bomsel, 1997). In contrast, ectocervical and vaginal epithelium is 
composed of pluristratified epithelial cells that lack a polarized plasma membrane and tight 
junctions, allowing intraepithelial dendritic cells and Langerhans cells to diffuse into the 
epithelium (Bomsel and Alfsen, 2003). Depending on the site of infection, several 
mechanisms for HIV-1 transmission across mucosal epithelia have been proposed, including 
columnar epithelial cell transcytosis, direct infection of epithelial cells, and 
dendritic/Langerhans cell transport (Bomsel & David, 2002; Shattock et al., 2000).  
The major type of HIV transcytosis is cell-associated (Bomsel & Alfsen, 2003), generated by 
cell-cell contact of virally-infected cells with apical epithelial cell surfaces. It is a rapid, 
efficient, and nondegradative process in which virus is transported from the apical to the 
basolateral surface of polarized epithelial cells. Cell-free virus transcytosis is also possible 
but inefficient (Bobardt et al., 2007; Bomsel, 1997). Rather than fusion and infection, 
interactions between viral components, including gp41 (Alfsen et al., 2001), gp120 (Bobardt 
et al., 2007), and gp160 (Hocini et al., 1997), and host epithelial cell surface molecules, such 
as glycosphingolipid galactosyl-ceramide (GalCer) (Alfsen & Bomsel, 2002; Meng et al., 
2002), an important component of endocytotic “raft” membrane microdomains, the 
coreceptor CCR5 (Bomsel et al., 2007), and the heparin sulfate proteoglycan attachment 
receptor, agrin (Alfsen et al., 2005), lead to transcytosis of the virus across the epithelial 
barrier and its trapping by submucosal dendritic cells which disseminate it to target CD4+ T 
cells.  
Immunoglobulin A (IgA) and immunoglobulin G (IgG) anti-HIV antibodies have been 
detected in nearly all external secretions. Although mucosal IgG may interfere with viral 
infection in tissues underlying mucosal epithelia and secondary lymphoid tissues, mucosal 
IgA is thought to best protect mucosal surfaces (Pope and Haase, 2003). HIV-1 entry via 
transcytosis in vitro can be inhibited by dimeric IgA (dIgA) isolated from HIV-1-infected 
subjects (Bomsel et al., 1998), secretory IgA specific for gp41 (Alfsen et al., 2001), and 
mucosal and serum IgA from HIV-1-exposed seronegative individuals (Devito et al., 2000). 
Recently, transcytosis inhibition of both SIV and SHIV by vaccine-elicited mucosal 
antibodies has been evaluated in pre-clinical studies in non-human primates. In rhesus 
macaques, mucosal priming with replication-competent Ad-HIV or SIV recombinants 
followed by intramuscular boosting with envelope protein elicited antibodies in rectal 
secretions able to inhibit SIV and SHIV transcytosis in vitro (Hidajat et al., 2009; Xiao et al., 
2010). Importantly, a significant correlation between transcytosis inhibition and reduced 
chronic viremia was seen in the study by Xiao et al. (2010) suggesting that mucosal IgA 
present in the submucosa may play a role in viremia control during the course of infection. 
However, the strongest evidence to date for a contribution of transcytosis inhibition to 
vaccine-elicited protection was recently reported by Bomsel et al. (2011). Following 
intramuscular plus intranasal immunization with gp41 subunit immunogens on virosomes, 
4 out of 5 rhesus macaques were protected from SHIVSF162P3 acquisition following repetitive 
low-dose challenge, whereas all controls became infected. The protected macaques had 
www.intechopen.com
 HIV Envelope-Specific Antibody and Vaccine Efficacy   
 
267 
gp41-specific vaginal IgA that mediated transcytosis inhibition, and vaginal IgG that had 
neutralizing and/or ADCC activity. Both the transcytosis inhibition and ADCC activity 
were significantly inversely correlated with acute viremia. Of particular interest, sera from 
these macaques lacked anti-HIV activity in neutralization, ADCC, and transcytosis 
inhibition assays, suggesting that the IgG with protective activity was locally produced. A 
similar suggestion was reported in the study of Xiao et al. (2010).  
5. Antibody avidity 
In addition to functionality, the overall quality of an antibody response largely determines 
its effectiveness. Antibody avidity, a measure of the strength of the binding interaction 
between an antigen with multiple antigenic determinants and multivalent antibodies 
(Siegrist et al., 2004), is one characteristic which contributes to efficacy. It develops in 
germinal centers following somatic hypermutation of immunoglobulin genes and selection 
of B cells for high affinity binding to antigen (Berek et al., 1991; French et al., 1989; Griffiths 
et al., 1984). Thus, this antibody maturation process is dependent on both time and antigen 
exposure. The importance of antibody avidity has been shown in studies associating low 
antibody avidity with poor protective efficacy of an RSV vaccine (Delgado et al., 2009). In 
contrast, high-avidity neutralizing (Barnett et al., 2010) and non-neutralizing (Zhao et al., 
2009; Xiao et al., 2010) HIV-1 Env-specific antibodies have been inversely correlated with 
reduced SHIV viremia following challenge. Importantly, in the Xiao et al. (2010) study, 
significant correlations were seen between antibody avidity and both functional antibody 
activities: ADCC and ADCVI, both also correlated with reduced viremia. The results overall 
suggest that antibody maturation following vaccination is associated with better functional 
antibody activity.  
6. The role of memory B cells in vaccine-mediated immunity 
A critical feature of protective humoral immunity is memory. The success of vaccination 
depends on the differentiation of naïve B cells into plasma cells and memory B cells. Plasma 
cells are terminally differentiated and continuously secrete antibody without requiring 
further antigenic stimulation. In contrast, memory B cells represent an important second line 
of immune defense that is initiated if pre-existing antibody levels are too low to prevent 
infection or if an invading pathogen is able to circumvent the pre-existing antibody 
response. Memory B cells do not actively secrete antibody but instead maintain their 
immunoglobulin in the membrane-bound form, which together with Ig┙ and Ig┚ form the 
antigen-specific B cell receptor. Following exposure to the initial antigen these cells become 
fully activated, proliferate, and differentiate into antibody secreting cells (ASC) (Ahmed & 
Gray, 1996; McHeyzer-Williams & McHeyzer-Williams, 2005; Pierce & Liu, 2010). Little is 
understood about the regulation of vaccine-induced humoral immunity. Differentiation of 
memory B cells into short-lived plasma cells is dependent on the presence of antigen 
(Dorner & Radbruch, 2007; Cagigi, et al., 2008). In contrast, long-lived antibody responses 
generated by viral infections or vaccinations are not dependent on the continuous presence 
of memory B cells but are rather produced by long-lived plasma cells that reside in the bone 
marrow and do not require antigen for continued production of antibody (Dorner & 
Radbruch, 2007; Radbruch et al., 2006). In fact, vaccine-induced B cell memory is maintained 
for more than 50 years after smallpox vaccination (Crotty et al., 2003), whereas antibody 
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responses to tetanus toxoid and diphtheria vaccines have half-lives of 11 and 19 years, 
respectively (Amanna et al., 2007). 
Memory B cell and serum antibody levels do not always correlate. This lack of correlation 
implies that the serum antibody level is maintained by long-lived plasma cells in the bone 
marrow and not by memory B cells circulating in the blood. However, in one of the first 
studies to examine the frequency of specific memory B cells in humans (Bonsignori et al., 
2009), plasma antibody and memory B cell responses to HIV-1 envelope were compared in a 
group of chronic HIV-1 infected individuals and in volunteers vaccinated in the VAX004 
clinical trial (Gilbert et al., 2005). A significant correlation between blood anti-Env memory B 
cells levels and plasma anti-Env antibody titers was found in both chronic HIV-1 infection 
and after vaccination with rgp120, suggesting that plasma antibody was maintained 
predominantly by short-lived memory B cells. Additionally, the half-life of anti-Env 
antibodies was shorter than those for influenza and tetanus toxoid, demonstrating that the 
HIV-1 envelope does not elicit long-lived B cell memory to the degree of other antigens. This 
outcome is not surprising for the HIV-infected cohort, as B-cell dysfunction, including loss 
of memory B cell subsets has been well-documented in HIV and SIV infection (Cagigi et al., 
2008; Kuhrt et al., 2010a; Shen & Tomaras, 2011). However, the reasons for impaired 
memory induction in vaccinees is not well understood, and may include immune 
suppression due to binding of gp120 to CD4 or binding of carbohydrates to mannose 
receptors on dendritic cells and B cells (Bonsignori et al., 2009).    
SIV and SHIV non-human primate models have been very valuable in HIV vaccine 
development. Human memory B cells have been extensively studied (Bonsignori et al., 2009; 
Crotty et al., 2004; Bernasconi et al., 2002), but only recently have rhesus macaque memory B 
cell studies been undertaken (Douagi et al., 2010; Kuhrt et al., 2010). We have recently 
shown induction of SIV and HIV Env-specific IgG and IgA ASC in rhesus macaques 
following priming with replicating Ad-SIV or HIV recombinants and boosting with SIV or 
HIV envelope protein (Brocca-Cofano et al., 2011). Env-specific IgG and IgA specific 
activities were correlated with several antibody activities, including ADCC, ADCVI, and/or 
transcytosis inhibition, indicating that maturation of antibody responses is critical for 
improved functionality. Further, IgG and IgA memory B cells post challenge were inversely 
correlated with chronic viremia indicating that vaccine-induced memory B cells were 
recalled and influenced disease outcome. That memory B cells should exhibit a protective 
role is not surprising in view of the reported association between loss of memory B cells and 
rapid disease progression in both HIV and SIV infection (Titanji et al., 2006; Titanji et al., 
2010). Our induction of strong anti-envelope memory B cell responses by vaccination 
(Brocca-Cofano et al., 2011) may reflect use of a replicating vector to prime immune 
responses followed by envelope boosting. The combined approach may have provided both 
the antigen persistence and time necessary to allow antibody maturation.  
7. Conclusion 
Antibodies are key to host defense and critical for HIV vaccine design. Antibodies that 
recognize conserved epitopes and broadly neutralize virus can prevent infection. Once 
infection has occurred, other antibodies that interact with viral antigens expressed on the 
infected cell surface are needed to eliminate initial foci, or control subsequent systemic 
spread of the virus. Fc receptor-bearing effector cells, such as NK cells, can mediate killing 
of infected cells by ADCC and/or ADCVI activities. The latter can also inhibit viral 
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replication. Mucosal antibodies that block viral entry through mechanisms such as 
transcytosis inhibition help control viral transmission and spread. As summarized here, 
maturation of vaccine-induced antibody responses is necessary for optimal function. Both 
antibody avidity and memory are directly associated with functional activity and control of 
viremia. An HIV/AIDS vaccine should be able to induce both cellular and humoral 
immunity. Regarding the latter, the success of a vaccine will depend on stimulating the 
production of mature high-titered antibodies with sufficiently broad reactivity to protect 
against HIV and SIV encounters. The path to induction of protective anti-envelope 
antibodies will come from understanding the B cell regulatory pathway of specific antibody 
production and from design of optimal immunogens. Coordination between human vaccine 
clinical trials and nonhuman primate vaccine challenge studies is essential to advance new 
vaccine concepts and accelerate the pace of HIV-1 vaccine efficacy trials. 
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knowledge on HIV/AIDS.
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